Canada Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostic, Therapeutic), By Application (Oncology, Bone Metastasis, Neurology, Cardiology), By End-use (Hospitals & Clinics, Diagnostic Centers), By Province, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1 Methodology and Scope
                    1.1 Market Segmentation
                        1.1.1 Market Definitions
                        1.1.2 Estimates And Forecast Timeline
                    1.2 Objectives
                        1.2.1 Objective - 1
                        1.2.2 Objective - 2
                        1.2.3 Objective - 3
                    1.3 Research Methodology
                    1.4 Information Procurement
                        1.4.1 Purchased Database
                        1.4.2 Gvr’s Internal Database
                        1.4.3 Secondary Sources
                        1.4.4 Primary Research
                        1.4.5 Details Of Primary Research
                    1.5 Information Or Data Analysis
                        1.5.1 Data Analysis Models
                    1.6 Market Formulation & Validation
                    1.7 Model Details
                        1.7.1 Commodity Flow Analysis
                            1.7.1.1 Approach 1: Commodity Flow Approach
                            1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
                    1.8 List of Secondary Sources
                    1.9 List of Abbreviations
Chapter 2 Executive Summary
                    2.1 Market Snapshot
                    2.2 Product and End-Use Segment Snapshot
                    2.3 Application Segment Snapshot
                    2.4 Competitive Landscape Snapshot
Chapter 3 Canada Nuclear Medicine Market Variables, Trends, and Scope
                    3.1 Canada Nuclear Medicine Market Lineage Outlook
                        3.1.1 Parent Market Outlook
                        3.1.2 Ancillary Market
                    3.2 Market Dynamics
                        3.2.1 Market Driver Analysis
                            3.2.1.1 Rising Incidence Of Cancer And Cardiovascular Diseases
                            3.2.1.2 Increasing Applications Of Radiopharmaceuticals/Nuclear Medicine
                            3.2.1.3 Growing Demand For Accurate Diagnostic Methods
                        3.2.2 Market Restraint Analysis
                            3.2.2.1 Stringent Regulations Pertaining To Production, Storage, & Usage Of Nuclear Medicine & Radiopharmaceuticals
                            3.2.2.2 High Costs Associated With Diagnostics & Therapeutic Procedures
                    3.3 Canada Nuclear Medicine Market Analysis Tools
                        3.3.1 Porter’s Five Forces Analysis
                        3.3.2 Pestle Analysis
                    3.4 Market Trends
                        3.4.1 Spect Radioisotopes Trends
                        3.4.2 Pet Radioisotopes Trends
                        3.4.3 Therapeutic Radioisotope Trends
                    3.5 COVID-19 Impact
                    3.6 Pipeline Analysis
Chapter 4 Canada Nuclear Medicine Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
                    4.1 Canada Nuclear Medicine Market: Product Movement Analysis
                    4.2 Canada Nuclear Medicine Market Estimates & Forecast, By Product (USD Million)
                        4.2.1 Diagnostic Products
                            4.2.1.1 SPECT
                                4.2.1.1.1 TC-99m
                                4.2.1.1.2 TL-201
                                4.2.1.1.3 GA-67
                                4.2.1.1.4 I-123
                                4.2.1.1.5 Other SPECT products
                            4.2.1.2 PET
                                4.2.1.2.1 F-18
                                4.2.1.2.2 SR-82/RB-82
                                4.2.1.2.3 Other PET products
                        4.2.2 Therapeutic Products
                            4.2.2.1 Alpha Emitters
                                4.2.2.1.1 RA-223
                                4.2.2.1.2 Others
                            4.2.2.2 Beta Emitters
                                4.2.2.2.1 I-131
                                4.2.2.2.2 Y-90
                                4.2.2.2.3 SM-153
                                4.2.2.2.4 Re-186
                                4.2.2.2.5 Lu-117
                                4.2.2.2.6 Other beta emitters
                            4.2.2.3 Brachytherapy
                                4.2.2.3.1 Cesium-131
                                4.2.2.3.2 Iodine-125
                                4.2.2.3.3 Palladium-103
                                4.2.2.3.4 Iridium-192
                                4.2.2.3.5 Other Brachytherapy Products
Chapter 5 Canada Nuclear Medicine Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
                    5.1 Canada Nuclear Medicine Market: Application Movement Analysis
                    5.2 Canada Nuclear Medicine Market Estimates & Forecast, by Application (USD Million)
                        5.2.1 Cardiovascular Disorders
                        5.2.2 Neurology
                        5.2.3 Oncology
                        5.2.4 Thyroid
                        5.2.5 Lymphoma
                        5.2.6 Bone Metastasis
                        5.2.7 Endocrine Tumor
                        5.2.8 Others
Chapter 6 Canada Nuclear Medicine Market - Segment Analysis, by End Use, 2018 - 2030 (USD Million)
                    6.1 Canada Nuclear Medicine Market: End-Use Movement Analysis
                    6.2 Canada Nuclear Medicine Market Estimates & Forecast, By End Use (USD Million)
                        6.2.1 Hospitals & Clinics
                        6.2.2 Diagnostic Centers
                        6.2.3 Others
Chapter 7 Canada Nuclear Medicine Market - Province Analysis, by Product, Application, End Use, 2018 - 2030 (USD Million)
                    7.1 Canada
                        7.1.1 Alberta
                        7.1.2 Saskatchewan
                        7.1.3 Manitoba
                        7.1.4 Rest of Canada
Chapter 8 Competitive Landscape
                    8.1 Company Profiles
                        8.1.1 GE Healthcare
                            8.1.1.1 Company Overview
                            8.1.1.2 Financial Performance
                            8.1.1.3 Product Benchmarking
                            8.1.1.4 Strategic Initiatives
                        8.1.2 Nordion (Canada), Inc.
                            8.1.2.1 Company Overview
                            8.1.2.2 Financial Performance
                            8.1.2.3 Product Benchmarking
                            8.1.2.4 Strategic Initiatives
                        8.1.3 Lantheus Medical Imaging, Inc.
                            8.1.3.1 Company Overview
                            8.1.3.2 Financial Performance
                            8.1.3.3 Product Benchmarking
                            8.1.3.4 Strategic Initiatives
                        8.1.4 Cardinal Health
                            8.1.4.1 Company Overview
                            8.1.4.2 Financial Performance
                            8.1.4.3 Product Benchmarking
                            8.1.4.4 Strategic Initiatives
                        8.1.5 Jubilant Life Sciences Ltd.
                            8.1.5.1 Company Overview
                            8.1.5.2 Financial Performance
                            8.1.5.3 Product Benchmarking
                            8.1.5.4 Strategic Initiatives
                        8.1.6 Isologic Innovative Radiopharmaceuticals
                            8.1.6.1 Company Overview
                            8.1.6.2 Financial Performance
                            8.1.6.3 Product Benchmarking
                            8.1.6.4 Strategic Initiatives
                        8.1.7 Curium Pharma
                            8.1.7.1 Company Overview
                            8.1.7.2 Financial Performance
                            8.1.7.3 Product Benchmarking
                            8.1.7.4 Strategic Initiatives
                        8.1.8 adMare BioInnovations
                            8.1.8.1 Company Overview
                            8.1.8.2 Financial Performance
                            8.1.8.3 Product Benchmarking
                            8.1.8.4 Strategic Initiatives
                    8.2 Company Market Share Analysis, 2023
Chapter 9 Conclusion

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Key products currently undergoing clinical trials
Table 4 Pipeline product status as on company website
Table 5 Canada Nuclear Medicine market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)
Table 6 Canada Nuclear Medicine market revenue estimates and forecast, by application, 2018 - 2030 (USD Million)
Table 7 Canada nuclear medicine market revenue estimates and forecast, by end-use, 2018 - 2030 (USD Million)
Table 8 Company market share, 2023
Table 9 Key companies undergoing expansions
Table 10 Key companies undergoing collaborations
Table 11 Key companies undergoing new product launches
Table 12 Key companies undertaking acquisitions
Table 13 Key companies undertaking other activities

List of Figures

Fig. 1 Canada Nuclear Medicine Market Segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Product and end-use segment snapshot
Fig. 11 Application segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Pharmaceutical market value, 2023 (USD Billion)
Fig. 14 Market dynamics
Fig. 15 Most common cancer forms diagnosed in Canada, 2023
Fig. 16 Porter’s Five Forces analysis
Fig. 17 PESTLE analysis
Fig. 18 Production of SPECT radioisotopes
Fig. 19 Production of PET radioisotopes
Fig. 20 Canada Nuclear Medicine market: Product outlook and key takeaways
Fig. 21 Canada Nuclear Medicine market: Product movement analysis
Fig. 22 Diagnostic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 SPECT market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 TC-99m market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 TL-201 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 GA-67 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 I-123 Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Other SPECT products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 PET market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 F-18 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 SR-82/RB-82 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Other PET products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Therapeutic products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Alpha emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 RA-223 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 I-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Y-90 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 SM-153 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Re-186 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Lu-117 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Other beta emitters market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Brachytherapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Cesium-131 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Iodine-125 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Palladium-103 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Iridium-192 market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Other brachytherapy products market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Canada Nuclear Medicine market: Application outlook and key takeaways
Fig. 51 Canada Nuclear Medicine market: Application movement analysis
Fig. 52 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Thyroid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Lymphoma market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Bone metastasis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Endocrine tumor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Canada nuclear medicine market: End-use outlook and key takeaways
Fig. 61 Canada nuclear medicine market: End-use movement analysis
Fig. 62 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Alberta market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Saskatchewan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Manitoba market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Rest of Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Key company categorization